These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33834412)

  • 1. "Novel Psychopharmacology for Depressive Disorders".
    Fornaro M; De Berardis D; Anastasia A; Fusco A
    Adv Exp Med Biol; 2021; 1305():449-461. PubMed ID: 33834412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine in the Treatment of Depressive Episodes.
    Ritter P; Findeis H; Bauer M
    Pharmacopsychiatry; 2020 Mar; 53(2):45-50. PubMed ID: 31434140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
    Fava M; Stahl SM; De Martin S; Mattarei A; Bettini E; Comai S; Alimonti A; Bifari F; Pani L; Folli F; Guidetti C; Furlan A; Sgrignani J; Locatelli P; Cavalli A; O'Gorman C; Traversa S; Inturrisi CE; Pappagallo M; Manfredi PL
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1463-1476. PubMed ID: 36890259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
    Lengvenyte A; Strumila R; Olié E; Courtet P
    Eur Neuropsychopharmacol; 2022 Apr; 57():88-104. PubMed ID: 35219097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate-based antidepressants: preclinical psychopharmacology.
    Pilc A; Wierońska JM; Skolnick P
    Biol Psychiatry; 2013 Jun; 73(12):1125-32. PubMed ID: 23453290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
    Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
    Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
    Nikayin S; Sanacora G
    CNS Drugs; 2021 Oct; 35(10):1069-1079. PubMed ID: 34491545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A letter to the editor, associated with the article entitled "Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketamine vs lithium" by Vázquez et al. (
    Terao I; Honyashiki M; Inoue T
    J Psychopharmacol; 2022 May; 36(5):653-654. PubMed ID: 35475361
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.